1.0-1.1 billion for 2016....vs exp. 1.2-1.3b
a bit short. but i think ok for now. very much priced in and the guidance is actually not as bad as some feared. great to finally get that number from the company.
they digested what management says and we get better ideas where things stand now and going forward...they like what they read and saw...they see the stock being cheap down here...110 by end of year is what wall street expects...vrtx owns the cf market.
not gonna be 20. management wouldn't entertain this kind of offer and certainly won't need to hire a firm to halp with the trouble for 20/share
i expect 35 plus...
give them another qtr or so...once they get more data, they will be able to provide better guidance...
vrtx didn't provide guidance on orkambi until last week, when the drug was approved last year and a few qtr's sales in the books.
the stock runs up about 15 percents. and the company issues secondary asap to close it before it comes back to the teens...bears will come out with articles to point out how fda still may not approve the drug because the question of efficacy and safety. take your profit tomorrow if you can.